Auszug
Alkohol ist einedirty drug und interagiert mit zahlreichen Neurotransmittern im Gehirn, inklusive Dopamin, Serotonin, GABA, Glutamat und Opioiden. Die Interaktionen sind komplex, da Alkohol in unterschiedlicher Dosierung die Rezeptoren unterschiedlich stark beeinflusst und eine Akute und eine chronische Alkoholwirkung zu unterscheiden sind.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Anton RF, Swift RM (2003) Current pharmacotherapies for alcoholism: U.S. Perspective. Am J Addict 12(Suppl 1): 553–568
Anton RF, Moak DH, Waid L, Latham PK, Malcolm RJ, Dias JK (1999) Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial. Am J Psychiatry 156: 1758–1764
Anton, RF, Moak DH, Latham PK, Wald LR, Malcolm RJ, Dias JK, Roberts JS (2001) Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism. J Clin Psychopharmacol 21: 72–77
Anton RF, O’Malley SS, Ciraulo DA et al (2006) Combined pharmacotheraples and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295: 2003–2017
Balldin J, Berglund M, Borg S et al (2003) A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol Clin Exp Res 27: 1142–1149
Baltieri DA, de Andrade AG (2003) Efficacy of a camprosate in the treatment of alcohol-dependent outpatients. Rev Bras Psiquiatr 25: 156–159
Barrias JA, Chabac S, Ferreira L, Fonte A, Potgieter AS (1997) Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psyquiatr Clin 18: 49–160
Berglund M, Andreasson S, Franck J, Fridell M, Hakanson I, Johansson BA (2001) Treatment of alcohol and drug abuse-an evidence-based review. Swedish Council on Technology Assessment in Health Care (SBU); Vol 1: Report No. 156
Besson J, Aeby, F, Kasas A, Lehert P, Potgieter A (1998) Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcoholism: Clin Exp Res 22(3): 573–579
Bouza C, Magro A, Muñoz A, Amate JM (2004) Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction 99: 811–828
Cahill K, Stead L, Lancaster T (2007) Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 24(1): CD006103
Carroll KM, Nich C, Ball SA, McCance E, Frankforter TL, Rounsaville BJ (2000) One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: sustained effects of treatment. Addiction 95: 1335–1349
Chick J, Gough K, Falkowski W et al (1992) Disulfiram treatment of alcoholism. Br J Psychiatry 161: 84–89
Chick J, Howlett H, Morgan MY, Ritson B (2000a) United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcoholism 35: 176–187
Chick J, Anton R, Checinski K et al (2000b) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol 35: 587–593
Chu NS (1979) Carbamazepine: prevention of alcohol withdrawal selzures. Neurology 29: 1397–1401
Croop RS, Faulkner EB, Labriola DF (1997) The safety profile of naltrexone in the treatment of alcoholism. Arch Gen Psychiatry 54: 1130–1135
de Lima MS, de Oliveira Soares BG, Reisser AA, Farrell M (2002) Pharmacological treatment of cocaine dependence: a systematic review. Addiction 97: 931–949
Dole VP, Nyswander M (1965) A medical treatment for diacetylmorphine (heroin) addiction — a clinical trial with methadone hydrochloride. JAMA 193: 80–84
Froehlich JC, Zweifel M, Harts J, Lumeng L, Li TK (1991) Importance of delta opioid receptors in maintaining high alcohol drinking. Psychopharmacology (Berl) 103: 467–472
Fuller RK, Branchey L, Brightwell DR et al (1986) Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 256: 1449–1455
Gastpar M, Bonnet U, Boning J et al (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22(6): 592–598
Geerlings PJ, Ansoms C, van den Brink W (1997) Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in The Netherlands, Belgium and Luxembourg. Eur Addict Res 3: 129–137
Gianoulakis C, de Waele JP (1994) Genetics of alcoholism: role of the endogenous opioid system. Metab Brain Dis 9: 105–131
Gonzales D, Rennard SI, Nides M et al and Varenicline Phase 3 Study Group (2006). Varenicline, a 42 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation. JAMA 296: 47–55
Gual A, Lehert P (2001) Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcoholism 36(5): 413–418
Guardia J, Caso C, Arias F et al (2002) A double-blind, placebo controlled study of naltrexone in the treatment of alcohol dependence disorder: results from a multicenter clinical trial. Alcohol Clin Exp Res 26: 1381–1387
Heinala P, Alho H, Kilanmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD (2001) Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J Clin Psychophamacol 21: 287–292
Heinz A, Batra A (2003) Neurobiologie der Alkohol-und Nikotinabhängigkeit. Kohlhammer, Stuttgart
Hersh D, Van Kirk JR, Kranzler HR (1998) Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (Berl) 139(1): 44–52
Holbrook AM, Crowther R, Lotter A, Cheng C, King D (1999) Meta-analysis of benzodiazepine use in the treatment of acute alcohol withdrawal. CMAJ 9: 649–655
Hopkins JS, Garbutt JC, Poole CL, West SL, Carey TS (2002) Naltrexone and acamprosate: meta-analysis of two mediacal treatment for alcoholism. Alcohol Clin Exp Res 36(Suppl): 751
Johnson BA, Ait-Daoud N (2000) Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacology 149: 327–344
Johnson BA, Roache JD, Javors MA et al (2000) Ondansetron for reduction of drinking among blologically predisposed alcoholic patients. JAMA 284: 963–971
Johnson BA, Ait-Daoud N, Bowden CL et al (2003) Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 361: 1677–1685
Jorenby DE, Hays JT, Rigotti NA et al and Varenicline Phase 3 Study Group (2006) Efficacy of varenicline, anα4bβ2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA 296: 56–63
Kiefer F, Jahn H, Tarnaske T et al (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60: 92–99
Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, Anton RF (2004) Effectiveness of naltrexone in a community treatment program. Alcohol Clin Exp Res 28: 1710–1717
Koob GF, Mason BJ, De Witte P, Littleton J, Siggins GR (2002) Potential neuro-protective effects of acamprosate. Alc Clin Exp Res 26: 586–592
Kosten Tr, O’Connor PG (2003) Management of drug and alcohol with-drawal. N Engl J Med 348: 1786–1795
Kranzler HR, Van Kirk J (2001) Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res 25: 1335–1341
Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22: 493–503
Krishnan-Sarin S, Wand GS, Li XW, Portoghese PS, Froehlich JC (1998) Effect of muopioid receptor blockade on alcohol intake in rats bred for high alcohol drinking. Pharmacol Blochem Behav 59: 627–635
Krystal JH, Cramer JA, Krol WF et al (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345: 1734–1739
Ladewig D, Knecht T, Leher P, Fendl A (1993) Acamprosate — a stabilizing factor in long-term withdrawal of alcoholic patients. Ther Umsch 50: 182–188
Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med J Aust 176(11): 530–534
Lee A, Tan S, Lim D et al (2001) Naltrexone in the treatment of alcoholism — an effectiveness study in Singapore. Drug Alcohol Rev 20: 193–199
Lhuintre JP, Moore N, Tran G et al (1990) Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol 25: 613–622
Lhuintre JP, Daoust M, Moore ND et al (1985) Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancet 1: 1014–1016
Lucht M, Kuehn KU, Armbruster J et al (2003) Alcohol withdrawal treatment in intoxicated vs, non-into xicated patients: a controlled open-label study with tiapride/carbamazepine, clomethiazole and diazepam. Alcohol Alcohol 38: 168–175
Majumdar SK (1990) Chlormethiazole: current status in the treatment of the acute ethanol withdrawal syndrome. Drug Alcohol Depend 27: 201–207
Malcolm R, Myrick H, Brady KT, Ballenger JC (2001) Update on anticonvulsants for the treatment of alcohol withdrawal. Am J Addict 10(Suppl): 16–23
Mann K, Rommelspacher H (1999) Alkohol. In: Gastpar M, Mann K, Rommelspacher H (Hrsg) Lehrbuch der Suchterkrankungen. Thieme, Stuttgart
Mann K, Lehert P, Morgan MY (2004) Pharmacotherapy of alcohol dependence: a review of the clinical data. CNS Drugs 18: 485–504
Mason BJ (2001) Results of the multicenter study of acamprosate in the treatment of alcoholism. Biol Psychiatry 48: 77
Mason BJ, Salvato FR, Willams LD et al (1999) A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 56: 719–724
Mayo-Smith MF (1997) Pharmacological management of alcohol with-drawal: a metaanalysis and evidence-based practice guideline: American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 278: 144–151
Miotto K, McCann M, Basch J, Rawson R, Ling W (2002) Naltrexone and dsyphoria: factor or myth? Am J Addict 11: 151–160
Monti PM, Rohsenow DJ, Swift RM et al (2001) Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol Clin Exp Res 25: 1634–1647
Morley KC, Teesson M, Reid SC et al (2006) Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 101: 1451–1462
Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E (2001) Naltrexone for alcohol dependence. Addiction 96(11): 1565–1573
Mucha RF, Herz A (1985) Motivational properties, of kappa-and muoploid receptor agonists studied with place and taste preference conditioning procedure. Psychopharmacology (Berl) 86: 274–280
Mundle G, Banger M, Mugele B, Stetter F, Soyka M, Veltrup C, Schmidt LG (2003) AWMF-Behandlungsleitilnle: Akutbehandlung alkoholbezogener Störungen. Sucht 49: 147–167
Namkoong K, Lee BO, Lee PG, Choi MJ, Lee E, Investigators K.A.C.T. (2003) Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol 38: 135–141
Niederhofer H, Staffen W (2003) Acamprosate and its efficacy in treating alcohol dependent adolescents. Eur Child Adolesc Psychiatry 12: 144–148
O’Malley SS, Froehlich JC (2003) Advances in the use of naltrexone: an integration of preclinical, and clinical findings. Recent Dev Alcohol 16: 217–243
O’Malley SS, Jaffe AJ, Chang G et al (1992) Natrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatry 49: 876–887
O’Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B (1996) Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch Gen Psychiatry 53: 217–224
O’Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, O’Connor PG (2003) Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specially care: a nested sequence of 3 randomized trials. Arch Intern Med 163: 1695–1704
Oslin D, Liberto JG O’Brien J, Krois S, Norbeck J (1997) Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am J Geriatr Psychiatry 5: 324–332
Paille FM, Guelfi JD, Perkins AC, Royer RJ, Steru L, Parot P (1995) Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30: 239–247
Pelc I, Le Bon O, Lehert P, Verbanck P (1992) Acamprosate in the treatment of alcohol dependence: a six month postdetoxification study. In: Soyka M (ed) Acamprosate in relapse prevention of alcoholism. Springer, Berlin Heidelberg New York, pp 133–142
Pelc I, Verbanck P, Le Bon O, Gavrilovic M, Lion K, Lehert P (1997) Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dosefinding study. Br J Psychiatry 171: 73–77
Peters DH, Faulds D (1994) Tiapride. A review of its pharmacology and therapeutic potential in the management of alcohol dependence syndrome. Drugs 47: 1010–1032
Poldrugo F (1997) Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction 92: 1537–1546
Richmond R, Zwar N (2003) Review of buproprion for smoking cessation. Drug Alcohol Rev 22: 203–220
Rösner S, Leucht S, Lehert P, Soyka M (2007) Acamprosate supports abstinence, naltraxone prevents excessive drinking. Evidence from a meta-analysis with unreported outcomes. J Psychopharmacol, In press
Rousseaux JP, Hers D, Ferauge M (1996) Does acamprosate influence alcohol consumption of weaned alcoholics? J Pharm Belg 51: 65–68
Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T (2001) Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment. Alcohol Alcohol 36: 419–425
Sass H, Soyka M, Mann K, Zieglgänsberger W (1996) Relapse prevention by acamprosate: results from a placebo controlled study in alcohol dependence. Arch Gen Psychiatry 53: 673–680
Slattery J, Chick J, Cochrane M et al (2003) Prevention of relapse in alcohol dependence. Health Technology Assessment Report 3 Health Technology Board of Scotland Glasgow
Soyka M (1995) Die Alkoholkrankheit-Diagnostik und Therapie. Chapman & Hall, Weinheim
Soyka M (2003) Cannabis und mental health. Schmerz 17: 268–273
Soyka M, Chick J (2003) Use of acamprosate and opioid antagonists of alcohol dependence: European perspective. Am J Addict 12(Suppl 2): S69–80
Soyka M, Roesner S (2006) New pharmacological approaches for treatment of alcoholism. Expert Opin Pharmacother 7: 2341–2353
Soyka M, Morhart-Klute V, Horak M (2002) A combinantion of carbamazepine/tiapride in outpatient alcohol detoxification-results from an open clinical study. Eur Arch Psychiatry Clin Neurosci 252: 197–200
Soyka M, Schmidt P, Franz M et al (2006a) Treatment of alcohol withdrawal syndrome with a combination of tiapride/carbamazepine: results of a pooled analysis in 540 patients. Eur Arch Psychiatry Clin Neurosci 256: 395–401
Soyka M, Schmidt F, Schmidt P (2006b) Efficacy and safety of outpatient alcohol detoxification with a combination of tiapride/carbamazepine: additional evidence. Pharmacopsychiatry 39: 30–34
Soyka M, Banzer K, Erbas B, Koller G, Backmund M (2006c) Substitutionsbehandlung Drogenabhängiger — rechtliche Grundlagen und neue Ergebnisse der Therapieforschung. Nervenheikunde 25: 286–294
Spanagel R, Zieglgänsberger W (1997) Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol Sci 18: 37–65
Spanagel R, Putzke J, Stefferl A, Schobitz B, Zieglgansberger W (1996) Acamprosate and alcohol: II. Effects on alcohol withdrawal in the rat. Eur J Pharmacol 3: 45–50
Spanagel R, Pendyala G, Abarca C et al (2005) The clock gene Per2 influences the glutamatergic system and modulates alcohol consumption. Nature Med 11(2): 23–24
Stuppaeck CH, Pycha R, Miller C, Whitworth AB, Oberbauer H, Fleischhacker WW (1992) Carbamazepine versus oxazepam in the treatment of alcohol withdrawal: a double-blind study. Alcohol Alcohol 27: 153–158
Tabakoff B, Hoffman PL (1995) The biological aspects of alcoholism: implications for prevention treatment and policy. Hogrefe & Huber, Seattle, WA
Tempesta E, Janiri L, Bignamini A, Chabac S, Potgieter A (2000) Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol 35 202–209
Tonstad S, Tonnesen P, Hajek P, Williams KE, Billing CB, Reeves KR and Varenicline Phase 3 Study Group (2006) Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA 296: 64–71
Tsai G, Gasfriend DR, Coyle JT (1995) The glutamatergic basis of human alcoholism. Am J Psychiatry 152: 332–340
Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatry 49: 876–880
Volpicelli JR, Watson NT, King AC, Sherman CE, O’Brien CP (1995) Effect of naltrexone on alcohol »high« in, alcoholics. Am J Psychiatry 152: 613–615
Volpicelli JR, Rhines JS, Rhines KC, Volpicelli LA, Alterman AI, O’Brien CP (1997) Naltrexone and alcohol dependence: role of subject compliance. Arch Gen Psychiatry 54: 737–742
Whitworth AB, Fischer F, Lesch OM et al (1996) Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet 25: 1438–1442
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Soyka, M., Rösner, S. (2008). Medikamente zur Behandlung von Abhängigkeit und Entzugssymptomen. In: Holsboer, F., Gründer, G., Benkert, O. (eds) Handbuch der Psychopharmakotherapie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-68748-1_33
Download citation
DOI: https://doi.org/10.1007/978-3-540-68748-1_33
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-20475-6
Online ISBN: 978-3-540-68748-1
eBook Packages: Medicine (German Language)